A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Clinical trial NCT03131206 · TERMINATED

Trial details

NCT number: NCT03131206
Sponsor: Dana-Farber Cancer Institute
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer

Start date: 2017-06-19
Primary completion: 2018-11-08
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.